Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer.
Reads0
Chats0
TLDR
Comparing the outcomes from three prospective multicenter studies investigating the use of CTC to monitor patients undergoing treatment for metastatic breast, colorectal, or prostate cancer is compared and the CTC definition used in these studies is reviewed.Abstract:
The increasing number of treatment options for patients with metastatic carcinomas has created a concomitant need for new methods to monitor their use. Ideally, these modalities would be noninvasive, be independent of treatment, and provide quantitative real-time analysis of tumor activity in a variety of carcinomas. Assessment of circulating tumor cells (CTCs) shed into the blood during metastasis may satisfy this need. We developed the CellSearch System to enumerate CTC from 7.5 mL of venous blood. In this review we compare the outcomes from three prospective multicenter studies investigating the use of CTC to monitor patients undergoing treatment for metastatic breast (MBC), colorectal (MCRC), or prostate cancer (MPC) and review the CTC definition used in these studies. Evaluation of CTC at anytime during the course of disease allows assessment of patient prognosis and is predictive of overall survival.read more
Citations
More filters
Journal ArticleDOI
A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells
Elizabeth M. Matthew,Elizabeth M. Matthew,Lanlan Zhou,Lanlan Zhou,Zhaohai Yang,David T. Dicker,David T. Dicker,Sheldon L. Holder,Bora Lim,Bora Lim,Ramdane Harouaka,Siyang Zheng,Joseph J. Drabick,Nicholas E. Lamparella,Cristina I. Truica,Wafik S. El-Deiry,Wafik S. El-Deiry +16 more
TL;DR: A post-CellSearch CTC assay using multiplexed Q-dot or DyLight conjugated antibodies to detect multiple markers in single cells within a CTC population is developed, providing a noninvasive, diagnostic blood test as an adjunct to routine tissue biopsy.
Journal ArticleDOI
Health economic impact of liquid biopsies in cancer management.
Maarten Joost IJzerman,Maarten Joost IJzerman,A.M. Sofie Berghuis,Johann S. de Bono,Leon W.M.M. Terstappen +4 more
TL;DR: It is argued that (early stage) health economic research is required to facilitate liquid biopsies clinical use and to prioritize further evidence development.
Journal ArticleDOI
Currently Used Markers for CTC Isolation - Advantages, Limitations and Impact on Cancer Prognosis
TL;DR: This mini-review is specifically focused on what markers have been used for isolation of CTCs derived from solid cancers and on what are the advantages, limitations and impact of these markers.
Journal ArticleDOI
TOPK is highly expressed in circulating tumor cells, enabling metastasis of prostate cancer
Huimin Sun,Lei Zhang,Changhong Shi,Peizhen Hu,Wei Yan,Zhe Wang,Qiuhong Duan,Fan Lu,Lipeng Qin,Tao Lu,Juanjuan Xiao,Yingmei Wang,Feng Zhu,Chen Shao +13 more
TL;DR: It is found CTCs have significantly greater migratory capacity than parental cells, and high levels of TOPK in the tumors of patients were correlated with advanced stages of prostate cancer, especially for high-risk patients of Gleason score ≥8, PSA>20ng/ml.
Journal ArticleDOI
Integrative Analysis and Machine Learning based Characterization of Single Circulating Tumor Cells.
Arvind Iyer,Krishan Gupta,Shreya Sharma,Kishore Hari,Yi Fang Lee,Neevan Ramalingam,Yoon Sim Yap,Jay A. A. West,Ali Asgar S. Bhagat,Balaram Vishnu Subramani,Burhanuddin Sabuwala,Tuan Zea Tan,Jean Paul Thiery,Mohit Kumar Jolly,Naveen Ramalingam,Debarka Sengupta +15 more
TL;DR: It is shown that CTCs across cancers lie on a near-perfect continuum of epithelial to mesenchymal (EMT) transition and this classifier is used to validate circulating breast tumor cells captured using a newly developed microfluidic system for label-free enrichment of C TCs.
References
More filters
Journal ArticleDOI
The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited
TL;DR: It is now known that the potential of a tumour cell to metastasize depends on its interactions with the homeostatic factors that promote tumour-cell growth, survival, angiogenesis, invasion and metastasis.
Journal ArticleDOI
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Massimo Cristofanilli,G. Thomas Budd,Matthew J. Ellis,Alison Stopeck,Jeri Matera,M. Craig Miller,James M. Reuben,Gerald V. Doyle,W. Jeffrey Allard,Leon W.M.M. Terstappen,Daniel F. Hayes +10 more
TL;DR: The number of circulating tumor cells before treatment is an independent predictor of progression-free survival and overall survival in patients with metastatic breast cancer.
Journal ArticleDOI
Isolation of rare circulating tumour cells in cancer patients by microchip technology.
Sunitha Nagrath,Lecia V. Sequist,Shyamala Maheswaran,Daphne W. Bell,Daphne W. Bell,Daniel Irimia,Lindsey Ulkus,Matthew R. Smith,Eunice L. Kwak,Subba R. Digumarthy,Alona Muzikansky,Paula D. Ryan,Ulysses J. Balis,Ulysses J. Balis,Ronald G. Tompkins,Daniel A. Haber,Mehmet Toner +16 more
TL;DR: The CTC-chip successfully identified CTCs in the peripheral blood of patients with metastatic lung, prostate, pancreatic, breast and colon cancer in 115 of 116 samples, with a range of 5–1,281CTCs per ml and approximately 50% purity.
Journal ArticleDOI
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.
W. Jeffrey Allard,Jeri Matera,M. Craig Miller,Madeline Repollet,Mark Connelly,Chandra Rao,Arjan G.J. Tibbe,Jonathan W. Uhr,Leon W.M.M. Terstappen +8 more
TL;DR: The CellSearch system can be standardized across multiple laboratories and may be used to determine the clinical utility of CTCs, which are extremely rare in healthy subjects and patients with nonmalignant diseases but present in various metastatic carcinomas with a wide range of frequencies.
Journal ArticleDOI
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono,Howard I. Scher,R. Bruce Montgomery,Chris Parker,M. Craig Miller,H. Tissing,Gerald V. Doyle,Leon W.W.M. Terstappen,Kenneth J. Pienta,Derek Raghavan +9 more
TL;DR: CTC are the most accurate and independent predictor of OS in CRPC, and this data led to Food and Drug Administration clearance of this assay for the evaluation of CRPC.